Last reviewed · How we verify

NCT05344261

Effect of Prophylactic TMR and RPNI on Neuroma and Phantom Limb Pain

Withdrawn NA Last updated 5 December 2023
What this trial tests

NA trial testing Targeted Muscle Re-innervation in Amputation. Withdrawn.

Timeline
1 March 2023
Primary endpoint
30 December 2024
30 December 2024

Quick facts

Lead sponsorUniversity of Texas Southwestern Medical Center
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Start date1 March 2023
Primary completion30 December 2024
Estimated completion30 December 2024

Drugs / interventions tested

Conditions studied

Sponsor

University of Texas Southwestern Medical Center

Who can join

18 and older, any sex, with Amputation or Neuroma Amputation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to analyze the efficacy of novel interventions in post-amputation surgical care (specifically Targeted Muscle Reinnervation and Regenerative Peripheral Nerve Interface) on post-amputation pain and functional outcomes at the time of amputation. These novel interventions have been shown to be successful in treating the downstream effects of amputations (pain, phantom limb pain, neuroma pain, etc.), but has not been studied in a randomized manner at the time of amputation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Amputation

Currently open trials in the same condition.

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05344261.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing